Vtesse Inc., of Gaithersburg, Md., reported that phase I/II data from 14 patients with Niemann-Pick type C1 showed that after 12 months and 18 months of treatment with VTS-270, disease progression as measured by the NPC Neurological Severity Score was “significantly reduced” compared to data from a control group who did not receive the study drug. The data were presented at the Worldsymposium in San Diego. (See BioWorld Today, Jan. 8, 2015.)